Correction: Effect of a Stable Angiotensin-(1-7) Analogue on Progenitor Cell Recruitment and Cardiovascular Function Post Myocardial Infarction [J Am Heart Assoc.(2015); 4 (e001510)] DOI: 10.1161/JAHA.114.001510;Effect of a stable angiotensin-(1-7) analogue on progenitor cell recruitment and cardiovascular function post myocardial infarction

Journal of the American Heart Association

Volumn 4, Issue 2, 2015, Pages

  Pessôa, Bruno Sevá ^a   Becher, Peter Moritz ^c   Van Veghel, Richard ^a   De Vries, René ^a   Tempel, Dennie ^b   Sneep, Stefan ^a   Van Beusekom, Heleen ^a   Van Der Velden, Vincent H J ^a   Westermann, Dirk ^c   Jan Danser, A H ^a   Roks, Anton J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

Angiotensin (1 7); Cardiac function; Endothelial progenitor cells; Hemodynamics; Myocardial infarction; Renin angiotensin system; Vascular function

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANGIOTENSIN[1-7]; CYCLIC ANGIOTENSIN[1-7]; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANGIOGENIC FACTOR; ANGIOTENSIN I; ANGIOTENSIN I (1-7); PEPTIDE FRAGMENT; VASODILATOR AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DRUG EFFECT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CARDIOMEGALY; COMPLICATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; FLOW CYTOMETRY; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR;

ANGIOGENESIS INDUCING AGENTS; ANGIOTENSIN I; ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FLOW CYTOMETRY; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PEPTIDE FRAGMENTS; STEM CELLS; TIME FACTORS; VASODILATOR AGENTS;

EID: 85005914726     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.000649     Document Type: Erratum

References (53)

1. Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol. 2010;7:431-441.
2. Seva Pessoa B, van der Lubbe N, Verdonk K, Roks AJM, Hoorn EJ, Danser AHJ. Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol. 2013;9:26-36.
3. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol. 2008;585:303-312.
4. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, Raizada MK. Therapeutic implications of the vasoprotective axis of the reninangiotensin system in cardiovascular diseases. Hypertension. 2010;55:207-213.
5. Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, Ohara I, Murakoshi M, Aoki T, Ishikawa Y, Lee SH, Jeong KH, Lee TW, Ihm CG, Lim SJ, Tomino Y. Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. Am J Physiol Renal Physiol. 2011;300:F1271-F1282.
6. Shenoy V, Qi Y, Katovich MJ, Raizada MK. ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol. 2011;11:150-155.
7. Watts JA, Gellar MA, Stuart L, Obraztsova M, Marchick MR, Kline JA. Effects of angiotensin (1-7) upon right ventricular function in experimental rat pulmonary embolism. Histol Histopathol. 2011;26:1287-1294.
8. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, Raizada MK. Evidence for angiotensinconverting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:1048-1054.
9. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol. 2005;289:H2356-H2363.
10. Benter IF, Yousif MH, Al-Saleh FM, Raghupathy R, Chappell MC, Diz DI. Angiotensin-(1-7) blockade attenuates captopril-or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NGnitro-L-arginine methyl ester. J Cardiovasc Pharmacol. 2011;57:559-567.
11. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol. 2006;290:H684-H691.
12. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548-1550.
13. Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Sousa FB, Caliari MV, Silva GA, Melo MB, Nadu AP, Souza LE, Irigoyen MC, Almeida AP, Santos RA. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension. 2011;57:477-483.
14. Ferreira AJ, Oliveira TL, Castro MC, Almeida AP, Castro CH, Caliari MV, Gava E, Kitten GT, Santos RA. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci. 2007;81:916-923.
15. Wang Y, Qian C, Roks AJ, Westermann D, Schumacher SM, Escher F, Schoemaker RG, Reudelhuber TL, van Gilst WH, Schultheiss HP, Tschope C, Walther T. Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail. 2010;3:286-293.
16. van Beusekom HM, Schoemaker R, Roks AJ, Zijlstra F, van der Giessen WJ. Coronary stent healing, endothelialisation and the role of co-medication. Neth Heart J. 2007;15:395-396.
17. Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN, Haas M. Angiotensin-(1-7) with thioether bridge:an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther. 2009;328:849-854.
18. Durik M, van Veghel R, Kuipers A, Rink R, Haas Jimoh Akanbi M, Moll G, Danser AH, Roks AJ. The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction. Int J Hypertens. 2012;2012:536426.
19. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki KI, Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103:2776-2779.
20. Durik M, van Veghel R, Kuipers A, Rink R, Haas Jimoh Akanbi M, Moll G, Danser AH, Roks AJ. The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction. Int J Hypertens. 2012;536426.
21. de Vries L, Reitzema-Klein CE, Meter-Arkema A, van Dam A, Rink R, Moll GN, Akanbi MH. Oral and pulmonary delivery of thioether-bridged angiotensin-(1-7). Peptides. 2010;31:893-898.
22. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc. 2008;3:1422-1434.
23. Tempel D, de Boer M, van Deel ED, Haasdijk RA, Duncker DJ, Cheng C, Schulte-Merker S, Duckers HJ. Apelin enhances cardiac neovascularization after myocardial infarction by recruiting aplnr+ circulating cells. Circ Res. 2012;111:585-598.
24. Albinsson S, Shakirova Y, Rippe A, Baumgarten M, Rosengren BI, Rippe C, Hallmann R, Hellstrand P, Rippe B, Sward K. Arterial remodeling and plasma volume expansion in caveolin-1-deficient mice. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1222-R1231.
25. Swedberg K. Reduction in mortality by pharmacological therapy in congestive heart failure. Circulation. 1993;87:IV126-IV129.
26. Gschwend S, Buikema H, Henning RH, Pinto YM, de Zeeuw D, van Gilst WH. Endothelial dysfunction and infarct-size relate to impaired EDHF response in rat experimental chronic heart failure. Eur J Heart Fail. 2003;5:147-154.
27. Gschwend S, Henning RH, Pinto YM, de Zeeuw D, van Gilst WH, Buikema H. Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade. Br J Pharmacol. 2003;139:1317-1325.
28. Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S, Rodgers KE. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol. 2004;53:15-24.
29. Rodgers KE, Oliver J, diZerega GS. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol. 2006;57:559-568.
30. Rodgers KE, Xiong S, diZerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol. 2002;49:403-411.
31. Rodgers K, Xiong S, DiZerega GS. Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol. 2003;51:97-106.
32. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther. 2009;8:1676-1683.
33. Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 2007;67:2809-2815.
34. Rodgers K, Verco S, Bolton L, Dizerega G. Accelerated healing of diabetic wounds by NorLeu(3)-angiotensin (1-7). Expert Opin Investig Drugs. 2011;20:1575-1581.
35. Regenhardt RW, Mecca AP, Desland F, Ritucci-Chinni PF, Ludin JA, Greenstein D, Banuelos C, Bizon JL, Reinhard MK, Sumners C. Centrally administered angiotensin-(1-7) increases the survival of stroke-prone spontaneously hypertensive rats. Exp Physiol. 2014;99:442-453.
36. Regenhardt RW, Desland F, Mecca AP, Pioquinto DJ, Afzal A, Mocco J, Sumners C. Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology. 2013;71:154-163.
37. Mecca AP, Regenhardt RW, O'Connor TE, Joseph JP, Raizada MK, Katovich MJ, Sumners C. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011;96:1084-1096.
38. Santiago NM, Guimaraes PS, Sirvente RA, Oliveira LA, Irigoyen MC, Santos RA, Campagnole-Santos MJ. Lifetime overproduction of circulating angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertensioninduced cardiac dysfunction and remodeling. Hypertension. 2010;55:889-896.
39. Ferreira AJ, Castro CH, Guatimosim S, Almeida PW, Gomes ER, Dias-Peixoto MF, Alves MN, Fagundes-Moura CR, Rentzsch B, Gava E, Almeida AP, Guimaraes AM, Kitten GT, Reudelhuber T, Bader M, Santos RA. Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart. Ther Adv Cardiovasc Dis. 2010;4:83-96.
40. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol. 2006;290:H2417-H2423.
41. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007;292:H736-H742.
42. Marques FD, Melo MB, Souza LE, Irigoyen MC, Sinisterra RD, de Sousa FB, Savergnini SQ, Braga VB, Ferreira AJ, Santos RA. Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats. Int J Hypertens. 2012;2012:795452.
43. Zeng WT, Chen WY, Leng XY, Tang LL, Sun XT, Li CL, Dai G. Impairment of cardiac function and remodeling induced by myocardial infarction in rats are attenuated by the nonpeptide angiotensin-(1-7) analog AVE 0991. Cardiovasc Ther. 2012;30:152-161.
44. Zhao YX, Yin HQ, Yu QT, Qiao Y, Dai HY, Zhang MX, Zhang L, Liu YF, Wang LC, de Liu S, Deng BP, Zhang YH, Pan CM, Song HD, Qu X, Jiang H, Liu CX, Lu XT, Liu B, Gao F, Dong B. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther. 2010;21:1545-1554.
45. Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK, Katovich MJ. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond). 2007;113:357-364.
46. Guimaraes GG, Santos SH, Oliveira ML, Pimenta-Velloso EP, Motta DF, Martins AS, Alenina N, Bader M, Santos RA, Campagnole-Santos MJ. Exercise induces renin-angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice. Peptides. 2012;38:54-61.
47. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, Raizada MK. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol. 2011;96:287-294.
48. Qi Y, Shenoy V, Wong F, Li H, Afzal A, Mocco J, Sumners C, Raizada MK, Katovich MJ. Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. Exp Physiol. 2011;96:863-874.
49. Dongaonkar RM, Stewart RH, Geissler HJ, Laine GA. Myocardial microvascular permeability, interstitial oedema, and compromised cardiac function. Cardiovasc Res. 2010;87:331-339.
50. Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, van Gilst WH. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension. 1999;34:296-301.
51. Roks AJ, Nijholt J, van Buiten A, van Gilst WH, de Zeeuw D, Henning RH. Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II. J Hypertens. 2004;22:2355-2361.
52. Lucchesi PA, Sabri A, Belmadani S, Matrougui K. Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressureinduced myogenic tone in mouse mesenteric resistance arteries. Circulation. 2004;110:3587-3593.
53. Akhtar S, Yousif MH, Dhaunsi GS, Chandrasekhar B, Al-Farsi O, Benter IF. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol. 2012;165:1390-1400.